Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis

Advances in Therapy

Volumn 25, Issue 9, 2008, Pages 858-870

  Luchs, Jodi ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b North Shore/Long Island Jewish Health System ^*  (United States)

Author keywords

AzaSite; Meibomian gland; Posterior blepharitis; Topical azithromycin; Warm compresses

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; EYE DROPS;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BLEPHARITIS; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS;

EID: 58149354575     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-008-0096-9     Document Type: Article

References (30)

1. Jackson WB. Blepharitis: current strategies for diagnosis and management. Can J O phthalmol. 2008;43:170-179. (Pubitemid 351518168)
2. Smith RE, Flowers CW Jr. Chronic blepharitis: a review. CLAO J. 1995;21:200-207.
3. Foulks GN, Bron AJ. Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classifcation, and grading. Ocul Surf. 2003;1:107-126. (Pubitemid 41263900)
4. McCulley JP, Dougherty JM. Bacterial aspects of chronic blepharitis. Trans Ophthalmol Soc U K. 1986;105:314-318. (Pubitemid 16030044)
5. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J O phthalmol. 1984;68:524-528. (Pubitemid 15135457)
6. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27:486-491. (Pubitemid 16116292)
7. Seal D, Ficker L, Ramakrishnan M, Wright P. Role of staphylococcal toxin production in blepharitis. Ophthalmology. 1990;97:1684-1688.
8. Mondino BJ, Caster AI, Dethlefs B. A rabbit model of staphylococcal blepharitis. Arch O phthalmol. 1987;105:409-412. (Pubitemid 17023310)
9. Ficker L, Ramakrishnan M, Seal D, Wright P. Role of cell-mediated immunity to staphylococci in blepharitis. Am J O phthalmol. 1991;111:473-479.
10. Yanof M, Fine B. Ocular Pathology. Philadelphia, PA: J. B. Lippincott; 1989.
11. Friedlaender MH, Protzko E. Clinical development of 1% azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy. Clin Ophthalmol. 2007;1:3-10.
12. Amsden GW. Anti-infammatory Effects of macrolides-an underappreciated beneft in the treatment of community-acquired respiratory tract infections and chronic infammatory pulmonary conditions? J Antimicrob Chemother. 2005;55:10-21. (Pubitemid 40192609)
13. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12-20. (Pubitemid 350236720)
14. Culic O, Erakovic V, Cepelak I, et al. Azithromycin modulates neutrophil function and circulating infammatory mediators in healthy human subjects. Eur J Pharmacol. 2002;450:277-289.
15. Ferris FL 3rd, Kassof A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982;94:91-96. (Pubitemid 12080556)
16. Early Treatment Diabetic Retinopathy Study Research Group. Early treatment diabetic retinopathy study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98:741-756.
17. Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin T e r. 2005;27:1329-1342. (Pubitemid 41598368)
18. Groden LR, Murphy B, Rodnite J, Genvert GI. Lid fora in blepharitis. Cornea. 1991;10:50-53.
19. Seal DV, McGill JI, Jacobs P, Liakos GM, Goulding NJ. Microbial and immunological investigations of chronic non-ulcerative blepharitis and meibomianitis. Br J Ophthalmol. 1985;69:604-611. (Pubitemid 15229318)
20. Bron AJ, Tifany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004;2:149-165.
21. McCulley JP, Shine WE. The lipid layer of tears: dependent on meibomian gland function. Exp Eye Res. 2004;78:361-365. (Pubitemid 38183312)
22. Song PI, Abraham TA, Park Y, et al. The expression of functional LPS receptor proteins CD14 and toll-like receptor 4 in human corneal cells. Invest Ophthalmol Vis Sci. 2001;42:2867-2877. (Pubitemid 33035285)
23. Dougherty JM, McCulley JP, Silvany RE, Meyer DR. The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci. Invest Ophthalmol Vis Sci. 1991;32:2970-2975.
24. Yoon KC, Jeong IY, Park YG, Yang SY. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437.
25. Barton K, Monroy DC, Nava A, Pfugfelder SC. Infammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology. 1997;104:1868-1874. (Pubitemid 28100344)
26. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pfugfelder SC. Pro-and anti-infammatory forms of interleukin-1 in the tear fuid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292. (Pubitemid 32848857)
27. Afonso AA, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pfugfelder SC. Tear fuid gelatinase B activity correlates with IL-1alpha concentration and fuorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci. 1999;40:2506-2512. (Pubitemid 29455477)
28. Perry HD, Doshi-Carnevale S, Donnenfeld ED, Solomon R, Biser SA, Bloom AH. Efcacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171-175. (Pubitemid 43362715)
29. Rubin M, Rao SN. Efcacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ter. 2006;22:47-53. (Pubitemid 43364080)
30. Kunert KS, Tisdale AS, Stern ME, Smith JA, Gipson IK. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch O phthalmol. 2000;118:1489-1496.